For years, the average American weight grew alongside the economy, reaching an obesity rate of nearly 40%. Yet, with the popularization of GLP-1 medications, analysts and academics are examining a completely new angle – what happens when millions of people suddenly want smaller lunches?
With more than half of Americans projected to be obese by 2030, the drugs have moved from niche treatments into a mass-market phenomenon. Originally developed to treat Type 2 diabetes, these drugs work by boosting insulin production, lowering blood sugar, slowing stomach emptying, and targeting brain regions associated with hunger.
The result is powerful appetite suppression, with users consuming up to 21% fewer calories. However, implications stretch far beyond the healthcare industry.
Read Next
Biotech
